Health Canada approves Eli Lilly’s oral GLP‑1 pill Foundayo for weight loss and diabetes

Health Canada authorized Eli Lilly’s daily oral GLP‑1 medication Foundayo, containing the non‑peptide agonist orforglipron. The pill is approved for adults with obesity or overweight with related conditions and also for type‑2 diabetes. Eli Lilly said the product should reach Canadian pharmacies in January.

The approval adds an oral GLP‑1 option to Eli Lilly’s Canadian portfolio, expanding its market beyond injectables. Novo Nordisk’s competing oral GLP‑1 pill remains pending approval, giving Eli Lilly a first‑mover advantage.

  • 1Health Canada granted approval on 13 November 2026.
  • 2The medication is named Foundayo and contains the active ingredient orforglipron.
  • 3Foundayo is approved for adults with obesity and for overweight adults with at least one related health problem such as high blood pressure or sleep apnea.
  • 4The pill is also authorized to treat type‑2 diabetes.
  • 5Eli Lilly expects the pills to be available in Canadian pharmacies in January 2027.

Sources